It is well known that chronic myeloid leukemia (CML) is associated with chromosomal translocation (i.e., Philadelphia chromosome), which encodes the BCR: ABL1 oncoprotein through the fusion of the BCR and ABL1 genes with active tyrosine kinase activity, so tyrosine kinase inhibitors (TKIs) are currently the cornerstone treatment of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.